SEC Form 4Coverage since May 22, 2026
$RXRX insider trading
Over the last 12 months, Recursion Pharmaceuticals insiders reported no purchases and 8 sales totaling $747K across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $747K 8 events
- Events · 12m
- 8 Form 4 filings, grouped
- Insiders · 12m
- 4 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $RXRX · 12Mvia TradingView
Top insiders · 12m
Borgeson Blake—3× · $366K
Bumpus Namandje—2× · $28K
Gibson Christopher—2× · $268K
Khan NajatCEO and President1× · $84K
All insider trades
8 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.25 | $98K | -0.5% | plan |
| Jul 7, 2026 | Borgeson BlakeD | ▼ Sale | 40,000 | $3.96 | $159K | -0.6% | plan |
| Jun 18, 2026 | Bumpus NamandjeD | ▼ Sale | 3,963 | $3.18 | $13K | -3% | plan |
| Jun 5, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.62 | $145K | -4.3% | plan |
| Jun 5, 2026 | Khan NajatCEO and President · O·D | ▼ Sale | 23,588 | $3.58 | $84K | -1.1% | plan |
| Jun 3, 2026 | Bumpus NamandjeD | ▼ Sale | 4,386 | $3.54 | $16K | -9.2% | plan |
| Jun 2, 2026 | Borgeson BlakeD | ▼ Sale | 30,000 | $3.68 | $110K | -0.5% | plan |
| May 22, 2026 | Gibson ChristopherD | ▼ Sale | 40,000 | $3.08 | $123K | -4.3% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $RXRX feed.